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Abstract 
Objective: Patients with chronic liver disease (CLD), both non-alcoholic fatty liver disease 
(NAFLD) and chronic hepatitis C (CHC), are at high risk of diabetes (T2D), but mechanisms 
are still unknown. Muscle/liver insulin resistance (IR) and pancreatic dysfunction are the 
major metabolic defects leading to T2D. However, if the risk of T2D in CLD patients is 
because of reduced insulin response and/or to IR, and the impact of liver histology has not 
been investigated. 
Design: We studied 220 non-T2D patients with chronic liver disease (129 NAFLD, BMI = 
27.3 kg/m2 ; 91 CHC, BMI = 25.0 kg/m2 ) that received a 75-gram oral glucose tolerance 
test (OGTT) with the measurement of glucose and insulin concentrations for 2 hours, 
glucose tolerance (NGT vs IGT) and liver biopsy. The results were compared to 26 controls 
(CT-NGT, BMI = 25.6 kg/m2 ). We evaluated peripheral insulin sensitivity (OGIS), OGTT-
insulin response (ΔAUC-I/ΔAUC-G) and disposition-index (DI = OGIS∙ΔAUC-I/ΔAUC-G) for 
the risk to develop T2D. 
Results: NAFLD had increased muscle IR (associated to NASH, steatosis and fibrosis), 
higher than in CHC or CT-NGT (OGIS = 8.9 vs 11.3 and 10.5 mL/min kg, P < .0001). In 
NAFLD, OGTT-insulin response (ΔAUC-I/ΔAUC-G) was the highest while it was significantly 
decreased in CHC (2.2 vs 1.1 and 1.6, NAFLD vs. CHC and CT-NGT, P < .005). The highest 
T2D risk (low DI) was observed in CHC-IGT (7.5), CHC-NGT (13.5) and NAFLD-IGT (10.8) vs 
CT-NGT (14.9, all P < .0001), but not in NAFL-NGT or NASH-NGT. 
Conclusion: We observed an increased T2D risk in NAFLD-IGT, CHC-IGT and CHC-NGT 
mainly because of reduced OGTT-insulin response, while insulin response in NAFLD-NGT 




In 2019, the global prevalence of type 2 diabetes (T2D) in adults aged 20-79 years was 
estimated to be 9.3%, but more importantly, more than half (50.1%) of subjects with T2D 
did not know to have the disease.1 Chronic liver disease (CLD) is a major risk factor for 
decreased glucose tolerance and development of type 2 diabetes (T2D).2-4 Among CLDs, 
non-alcoholic fatty liver disease (NAFLD) is now recognized as an emerging metabolic 
disease, associated with increased T2D risk and affecting almost 25% of the world 
population.5 Similarly, but to a less extent, exposure to hepatitis C virus (HCV) represents 
a well-known risk factor for T2D.6 Many studies have shown that all CLDs are associated 
with insulin resistance (IR) 7-9 although obesity is often not accounted as a covariate 
despite being an independent risk factor for IR and T2D. Moreover the impact of reduced 
β-cell function and insulin secretion on the risk of T2D in CLD is usually not investigated. 
In the pathophysiology of T2D, not only IR but also pancreatic β-cell function and insulin 
secretion play a major role.10-14 As subjects become insulin resistant (mainly in the 
periphery), their glucose tolerance is maintained until the amount of insulin secreted by the 
pancreas is no longer sufficient to overcome the muscle IR.8, 10, 11, 14 Both hepatic and 
pancreatic dysfunction are major defects that might explain the increased risk of T2D in 
subjects with liver disease. Alterations in hepatic glucose production and increased 
postprandial glycaemia are early signs of glucose intolerance14 especially in patients with 
advanced liver disease even if they have normal fasting glucose concentrations (FPG).15 
If and how IR and insulin secretion are altered in NAFLD and/or CHC patients is still 
unknown. The disposition index (DI, calculated from the insulin secretion factored by the 
insulin resistance) evaluates if the pancreatic insulin secretion is sufficient to overcome 
peripheral insulin resistance and maintain glycaemia within normal ranges.10, 16, 17 Indeed, 
a low disposition index has been shown to be an independent marker of development of 
T2D.17-20 However, to the best of our knowledge the disposition index has not been 
evaluated in patients with CLD diagnosed by liver biopsy. Moreover only few studies have 
investigated ß-cell function and insulin response to a glucose load in subjects with NAFLD 
or CHC.15, 21-25 Despite high hepatic fat accumulation and peripheral IR, ß-cell function was 
often found unaltered in NAFLD 21-23, 25 indicating that most of the patients with CLD are 
able to compensate their IR by increasing insulin secretion and/or decreasing hepatic 
insulin clearance. Previously, Grancini et al have evaluated insulin secretion and ß-cell 
function in 160 advanced cirrhotic patients candidates for liver transplantation (the great 
majority with HCV) that underwent OGTT finding that insulin secretion worsens with the 
worsening of liver disease, and transition from IGT to DM is driven primarily by ß-cell 
dysfunction.15 Narita et al have performed OGTT in patients with CHC but IR and ß-cell 
function were evaluated only according to glucose tolerance and not in relation to the 
histological severity of the disease.24 
Here we evaluated if and how the type of CLD (NAFLD vs CHC) and severity of liver 
disease (degree of liver fibrosis) are associated to reduced peripheral insulin sensitivity 
and insulin response during an OGTT and how the increased risk of T2D of subjects with 
liver disease (evaluated by the disposition index) is related to alterations of the pancreas-
liver cross-talk. 
METHODS 
2.1 Study subjects and protocol 
This is a post-hoc analysis of data of 220 non-diabetic patients with liver disease (NAFLD 
n = 129, CHC n = 91) that participated to other protocols and that had an OGTT and liver 
biopsy.26, 27 The protocol of data collection was part of the common clinical practice in the 
hospital units of University of Ancona and Torino. Clinical data have been already 
published26, 27 while the analysis of β-cell function is completely new. All subjects were 
requested to give their informed consent to the use of personal data, analyses and liver 
biopsy at time of admission. CHC patients were recruited in Ancona between 2003 and 
2005 and liver biopsy was performed to evaluate the degree of liver injury before the 
introduction of Fibroscan in the routine clinical management of these patients in order to 
define the degree of stage of liver injury and the need of antiviral treatment. CHC was 
defined by high transaminase values for more than 6 months and by the presence of 
serum HCV-RNA in the absence of coinfection with hepatitis B virus (hepatitis B surface 
antigen and core antibody-positive), autoimmune hepatitis, cholestatic (primary biliary 
cholangitis, primary sclerosing cholangitis) or genetic (haemochromatosis, a1-antitripsin 
deficiency, Wilson disease) liver disease. Subjects with pharmacologically treated diabetes 
or previous antiviral treatment were also excluded. The habitual alcohol intake in the last 
6 months was assessed by interviews extended to family members and general 
practitioners, and patients with alcohol consumption > 40 g/day were excluded. Other 
exclusion criteria were the presence of decompensated cirrhosis, the presence of HCC or 
non-hepatic neoplastic diseases or a low life expectancy because of comorbidities. 
NAFLD patients were recruited in Torino and criteria for performing liver biopsy were 
previously reported,26, 27 that is, chronically elevated aminotransferase levels (alanine 
aminotransferase (ALT) 1.5 times the upper normal limit for 6 months or more), negative 
hepatitis B (hepatitis B surface antigen and core antibody) and C (anti-HCV IgG) viral 
markers, absence of autoimmune hepatitis or coeliac disease, no evidence of genetic, 
drug-induced or cholestatic liver disease and alcohol consumption (ie less than 20 g/d). 
Moreover 26 healthy subjects (BMI = 25.6 kg/m2) previously tested with normal glucose 
tolerance (CT-NGT), without liver disease by ultrasound or, when not available, by fatty 
liver index, were used as control group. 
Liver biopsies were available in all CHC and NAFLD patients and were scored in a blinded 
manner by two pathologists at the University of Ancona (for CHC patients) and at the 
University of Turin (for NAFLD patients). Fibrosis was scored according to Metavir28 for 
CHC and Kleiner score for NAFLD.29 NASH was diagnosed by the joint presence of 
steatosis, ballooning and lobular inflammation.30 Patients with a fibrosis score ≥ F2 were 
defined as high fibrosis (HF). 
All subjects received an oral glucose tolerance test (OGTT, 75g) with analysis of the 
glucose and insulin profiles at 0, 30, 60, 90, and 120 minutes after glucose ingestion. Data 
in CHC and NAFLD patients were compared with those obtained in CT-NGT subjects that 
were divided according to their response to OGTT as insulin sensitive (NGT-IS) if 
OGIS > 9.8 mL/kg/min, vs insulin resistant (NGT-IR).26 
This study was approved by the Ethical Committees of the participating centers (550-586-
70-2009 for University of Turin and 205 731 for University of Ancona), regulating non-
interventional studies. Glucose concentrations were measured with an automated analyser 
(Beckman Instruments, Fullerton CA, USA; inter-assay coefficient of variation (CV) 4%) 
while insulin concentrations were measured by immune-histochemistry assay (AIA-PACK 
IRI, AIA-1200 system, Tosoh Co.) with intra- and inter-assay CVs for quality control < 7%) 
as described previously.26, 27 
2.2 Calculations 
Subjects were analysed utilizing the following categories: control subjects were divided 
according to their response to OGTT as insulin sensitive (NGT-IS) if 
OGIS > 9.8 mL/kg/min, vs insulin resistant (NGT-IR); CHC patients were divided according 
to genotype (G3 vs non-G3) or according to glucose tolerance (CHC-NGT vs CHC-IGT); 
NAFLD patients were further categorized as NAFL or NASH, or according to glucose 
tolerance (NAFL-NGT, NASH-NGT, NAFL-IGT, NASH-IGT). Patients were also analysed 
according to fibrosis score, that is, low (LF) fibrosis (F0-F1) vs high (HF) fibrosis (F2-F4). 
NAS score was calculated as the sum of scores for steatosis, lobular inflammation and 
ballooning.30 
Peripheral insulin sensitivity was assessed during OGTT by oral glucose insulin sensitivity 
(OGIS) index31 and at fasting by HOMA.32, 33 
Insulin response to OGTT was assessed by calculating the ratio of incremental area under 
the curve (AUC) of insulin to glucose ΔAUC-I/ΔAUC-G from 0-120 minutes.10 The rapid 
insulin response was assessed as ΔAUC-I/ΔAUC-G from 0-30 minutes (Insulinogenic 
index, IGI).34 
As previously stated, when subjects become insulin resistant (IR), normal glucose 
tolerance is maintained until amounts of insulin secreted by the pancreas are sufficient to 
overcome the muscle IR.8, 10, 11 The relationship between insulin sensitivity and insulin 
secretion is hyperbolic as shown by Bergman et al35 Thus, by measuring the insulin 
secretion factored insulin resistance (the so-called disposition index, DI = OGIS × ΔAUC-
I/ΔAUC-G) it is possible to evaluate if the pancreatic insulin secretion is sufficient to 
overcome peripheral insulin resistance and maintain glycaemia within normal ranges.10 
2.3 Statistical analysis 
For statistical analysis patients were grouped as NAFLD (n = 129, BMI = 27.3 kg/m2), CHC 
genotype 3 (G3, n = 20, BMI = 24.1 kg/m2) or CHC non-3 genotype (non-G3, n = 71, 
BMI = 25.2 kg/m2) since CHC genotype 3 is known to have a different metabolic profile 
from CHC non-3 genotype.7 CT subjects were grouped as insulin sensitive (NGT-IS) or 
insulin resistant (NGT-IR) according to their response to OGTT (ie NGT-IR if Oral Glucose 
Insulin Sensitivity index OGIS ≤ 9.8 ml/min kg)26, 27 to better identify differences because of 
liver disease vs IR. 
Data are given as the mean ± SE. Group differences were analysed by Student t test, 
Mann-Whitney test, and chi-squared test, for normally distributed, non-normally distributed 
and non-continuous variables respectively. Univariate analysis (Spearman correlation 
coefficient) was used to estimate associations among continuous variables in the whole 
dataset. A two-tailed P < .05 was considered statistically significant. The correlation 
coefficient and p-values are reported in the graphs as well as in the text. 
RESULTS 
3.1 Clinical characteristics of the study subjects 
We studied 220 non-diabetic patients with liver disease (NAFLD n = 129; CHC n = 20 for G3 and 
n = 71 for non-G3) and compared to 29 controls without liver disease (Table 1). Control subjects 
were further divided into two groups as insulin sensitive (NGT-IS) or insulin resistant (NGT-IR), 
according to OGIS ≤ 9.8 mL/min kg (Table 1). 
CHC patients had a mean BMI = 25.0 ± 0.4 kg/m2 (BMI = 24.1 ± 0.7 and 
25.2 ± 0.5 kg/m2 for G3 and non-G3 respectively) not different from NGT-IS subjects 
(BMI = 25.9 ± 0.8 kg/m2) while NAFLD patients (BMI = 27.3 ± 0.3 kg/m2) had a BMI slightly 
higher than CHC but not controls (Table 1). 
AST and ALT were significantly increased in CHC and NAFLD compared to NGT-IS, while 
GGT was increased only in NAFLD and CHC non-G3 (Table 1). 
Lipid profile was similar among the groups, although CHC tended to have lower total 
cholesterol concentrations. The highest triglyceride (TG) concentrations were observed in 
the NAFLD group as expected, and in CHC non-G3 (Table 1). 
Glucose tolerance in NAFLD vs CHC patients 
All patients underwent a standard OGTT with the measurement of glucose and insulin 
levels every 30 minutes for 2 hours to assess glucose tolerance (Figure 1). The great 
majority of the patients had normal glucose tolerance (74% of patients were NGT, 
Table 1). Based on OGIS index, control subjects were divided into insulin sensitive (NGT-
IS), if OGIS > 9.8 mL/kg/min, vs insulin resistant (NGT-IR). Fasting glucose concentrations 
were lower in CHC compared to NAFLD, and in CHC-G3 they were lower than in controls 
(Table 1). The great majority of the patients had normal fasting glucose concentrations 
(80% were NFG, ie <100 mg/dL) and a similar distribution was observed in both CHC and 
NAFLD (impaired fasting glucose, IFG, in 14% and 24% respectively, Table 1). 
The highest prevalence of impaired glucose tolerant (IGT) subjects was observed in CHC 
non-G3 (31%), while in NAFLD it was similar to CHC G3 and control subjects with insulin 
resistance (26%, 25% and 25% respectively, Table 1). A higher prevalence of IGT was 
observed also in NAFLD with F2-F4 (Table 2). 
Insulin sensitivity in NAFLD vs CHC patients 
Fasting insulin resistance was measured by HOMA that was increased only in NAFLD 
compared to CT-NGT. In CHC patients, HOMA was significantly lower than in NAFLD 
while there was no difference with CT-NGT despite a lower mean value (Table 1). 
Peripheral insulin sensitivity during OGTT was evaluated by OGIS index that is a surrogate 
measure of glucose clearance during OGTT.27, 31 In average, NAFLD had the lowest OGIS 
(8.9 mL/min kg vs 11.3 mL/min kg in CHC and 10.5 in NGT-IS ml/min kg, P < .0001). 
However, nearly half of the subjects with NAFLD (n = 55) had an OGIS index > 9.8 mL/min 
kg. On the contrary, subjects with CHC non-G3 had an OGIS similar to NGT-IS while CHC 
G3 were even more sensitive than NGT-IS (Table 1). 
When the analysis was performed only in non-obese subjects (ie BMI ≤ 30), that 
comprised the great majority of patients (85%, ie 167/200), the results were similar. 
In NAFLD, OGIS was negatively correlated to liver fat in biopsy (r = −0.31, P = .0005) 
while no correlation was found in patients with CHC. However, the prevalence of hepatic 
steatosis was extremely low in patients with CHC and non G3 genotype, while it was 
higher in the G3 genotype that has a viral pathogenesis (Table 1). 
Since a decrease in OGIS was previously associated to increased liver fibrosis in 
NAFLD,27 we also evaluated if the degree of liver fibrosis had an impact on either glucose 
clearance or insulin response (Table 2, Figure 2). In the entire cohort of subjects with liver 
disease, patients with advanced fibrosis (F3-F4) had decreased OGIS but, when evaluated 
separately, only in NAFLD, and not in CHC, reduced OGIS was associated to increased 
liver fibrosis and this remained significant also after adjusting for BMI and gender 
(partial r = −0.19, P = .02), but correlation was lost if further adjusted for age 
(partial r = −0.15, P = .08) (Figure 2 panel C). A NAS score greater than 3 (Figure 2 panel 
E) or the presence of NASH were both associated with significantly reduced OGIS. 
These data indicate that, although not diabetic, NAFLD patients show decreased 
peripheral insulin sensitivity compared to controls and this decrease is associated with a 
higher degree of liver injury. No modifications have been observed in either G3 and non-
G3 CHC patients compared to controls. 
 Insulin response to OGTT in NAFLD vs CHC patients 
Insulin response to OGTT was assessed by calculating the ΔAUC-I/ΔAUC-G from 0 to 
120 minutes (Figure 2 panel B). The highest fasting and OGTT insulin concentrations were 
observed in NAFLD (Figure 1, panel B) despite glucose concentrations were similar to 
NGT-IR and CHC, indicating a preserved capacity to maintain glucose tolerance by 
adjusting insulin secretion/hepatic insulin clearance. 
In subjects with NAFLD, the insulin response to increased glucose concentrations after 
OGTT was much higher than in CT-NGT while ΔAUC-I/ΔAUC-G was significantly lower in 
CHC compared to CT-NGT and NAFLD (1.1 vs 2.2 and 1.6, CHC vs NAFLD and NGT-
IS, P < .005) (Figure 1, panel B). 
In CHC G3 patients, fasting insulin concentrations were lower than in CT-NGT (Table 1) 
while during OGTT they increased as high as NGT-IR. However, CHC patients, especially 
those non-G3, had a reduced response in the first 30min, indicating a loss of first phase 
insulin secretion. In NAFLD, the insulinogenic (IGI) index that reflects the early insulin 
response was similar to NGT-IS (Table 1) while ΔAUC-I/ΔAUC-G was even higher than in 
NGT-IS (Figure 2 Panel B). 
In NAFLD, but not in CHC, ΔAUC-I/ΔAUC-G was negatively correlated to liver fat in biopsy 
(r = 0.20, P = .03). 
No significant association was found between insulin response (ΔAUC-I/ΔAUC-G) and the 
degree of liver fibrosis in either CHC or NAFLD (Table 2 and Figure 2 panel D), nor with 
NAS score (Figure 2 panel F) or presence of NASH. 
Taken together, these data indicate that the insulin levels after OGTT are increased in 
NAFLD patients to maintain glucose concentrations during OGTT within normal limits, 
while CHC patients have an insulin profile comparable to NGT-IR. 
Disposition index (DI) in NAFLD vs CHC 
In the above analyses, we have shown that patients with NAFLD were able to increase 
insulin response to overcome reduced insulin sensitivity and thus maintain glucose 
tolerance and do not develop hyperglycaemia and T2D. 
In each group, we evaluated the disposition index (DI calculated as the product of insulin 
response times insulin resistance sensitivity) according to glucose tolerance status (ie 
normal glucose tolerance, NGT, vs impaired glucose tolerance, IGT). DI is an index of 
pancreatic insulin response factored by insulin resistance and inversely associated to 
increased risk of ß-cell dysfunction and T2D.18, 19, 36 In Panel A of Figure 3 lines are the 
trajectories of insulin sensitivity and secretion for each given DI and explain why until the 
subjects remain on the same line they are maintaining a normal glucose tolerance (NGT), 
that is, the increased insulin response allows to compensate the reduced insulin 
sensitivity, and DI is preserved. NGT patients with NAFLD have the same DI, that is, 
similar risk to develop T2D, since NAFL-NGT, NASH-NGT and NGT-IS are on similar 
curve (ie similar DI = 24.6 ± 3.0, 18.2 ± 1.5 vs 18.0 ± 3.1, respectively, p = ns), despite 
different IR and insulin secretion (Figure 3, Panel B). 
DI was significantly decreased in CHC, particularly if IGT, but not in this group of NAFLD 
(11.8 ± vs 18.2 ± vs 16.8 ± in CHC vs NAFLD vs NGT-IS, P < .0001) confirming the above 
observation (Figure 4, Panel A). 
DI was not associated to the degree of steatosis, neither in NAFLD, nor in CHC and 
neither the degree of fibrosis was associated with DI (Figure 4 panel B), but DI was 
instead decreased with increased glucose intolerance in both NAFLD and CHC 
(Figure 3 panel B). NAFLD patients with increased NAS score and/or the presence of 
NASH had lower DI (Figure 4 panel C and D). 
DISCUSSION 
In this study, we evaluated data from 220 non-diabetic patients (NAFLD n = 129 and CHC 
n = 91) with liver biopsy to verify: (a) if and how the type (NAFLD vs CHC) and severity of 
liver disease (grade of liver inflammation and stage of fibrosis, and presence of NASH) are 
associated to reduced peripheral insulin sensitivity and/or reduced insulin response during 
an OGTT; (b) how the increased risk of T2D in subjects with liver disease (evaluated by 
the DI) is related to alterations in the pancreas-liver cross-talk. The results of this analysis 
indicate that, although not diabetic, NAFLD patients had decreased peripheral insulin 
sensitivity compared to controls and this decrease was associated with presence of NASH 
and a higher degree of liver injury, while insulin sensitivity of CHC patients was similar to 
controls. Insulin response to oral glucose load was increased in NAFLD patients compared 
to both NGT-IS and NGT-IR, but compatible with the degree of IR, so that glucose 
concentrations during OGTT were within normal limits. On the contrary, CHC patients had 
a reduced insulin profile comparable to NGT-IR. Considering the risk of T2D (indicated by 
a low DI) in CLD, the higher risk was observed in CHC and was not associated with the 
stage of fibrosis, but to the degree of glucose tolerance. This poses the attention on 
patients that were previously exposed to HCV since this might have altered ß-cell function 
thereby favouring the pathogenesis of T2D.37 
Epidemiological studies have shown that both NAFLD and CHC are major risk factors for 
decreased glucose tolerance and development of type 2 diabetes (T2D).2-4, 38 The 
prevalence of both diabetes and NAFLD is increasing1, 5 and it has been estimated that 
almost half of the subjects with diabetes do not know to have the disease since they still 
have normal fasting glucose concentrations.1 It is recognized that postprandial 
hyperglycaemia occurs much earlier than fasting glycaemia13 since the pancreatic insulin 
secretion in response to changes in glucose concentrations (eg after a meal) is often not 
sufficient to overcome the peripheral insulin resistance state, thus determining high 
postprandial glucose levels. Abnormalities in glucose tolerance occur frequently in chronic 
liver diseases,14 not only in the advanced state and even in patients with normal 
FPG,15 supporting the importance of performing oral glucose tolerance tests (OGTT). In 
the pathophysiology of T2D, IR and in particular impaired insulin secretion and ß-cell 
dysfunction are important risk factors, but if they are both altered in NAFLD and CHC 
patients is still not clear. 
The OGTT, with the simultaneous measurement of glucose and insulin concentrations, 
serves not only to assess glucose tolerance but also insulin secretion,10 insulin resistance 
in the muscle and liver27, 31 and increased risk to develop type 2 
diabetes.10, 19, 36 Peripheral and hepatic IR are characteristic features of patients with 
CHC7 or NAFLD,14 even if they are lean.39 In our recent paper in non-diabetic 
NAFLD,27 we have shown that, in non-diabetic NAFLD, glucose concentrations during 
OGTT were similar in obese and non-obese patients independent of the degree of liver 
steatosis, while fibrosis score F2-F4 was associated with increased glucose 
concentrations during OGTT independent of obesity. On the contrary, insulin 
concentrations were lower only in non-obese with low steatosis and fibrosis. 
We have found that insulin response during OGTT was higher in patients with NAFLD 
compared to the other groups (Figure 1) in line with other studies23, 27 although appropriate 
for their glucose tolerance status.14 On the contrary, in patients with CHC we have found 
that insulin sensitivity was similar to insulin sensitive of CT-NGT, while glucose-stimulated 
insulin release was reduced compared to both NAFLD and CT-NGT (Figure 2). Although 
HCV replicates principally in hepatocytes also other organs might be affected by the virus, 
like muscle and pancreas.7, 37, 40 This might explain the alterations in glucose metabolism 
and tolerance and insulin resistance often observed in CHC patients and their high risk to 
develop T2D.7, 15 Masini et al have analysed the pancreatic islets of patients with 
CHC37 finding that these patients have both morphological and functional defects, in 
particular reduced glucose-stimulated insulin release that agrees with our findings 
(Figure 2, panel B). It has been shown that peripheral insulin sensitivity and glucose 
metabolism parameters ameliorate after HCV eradication,41-43 but if ß-cell dysfunction 
improves after Directly Acting Antivirals, or if morphological and functional defects because 
of virus exposure are permanent, will need further investigation. 
The risk to develop T2D was assessed by the evaluation of the insulin secretion/insulin 
resistance relationship (also named disposition index, DI).10, 17 The disposition index 
follows a hyperbolic curve that indicates that, until the pancreatic insulin response 
compensates the reduced insulin sensitivity (see arrows in Figure 4), the subjects preserve 
their insulin tolerance status, while a decrease in DI indicates an increased risk of 
T2D.20, 35 With the decrease in DI, the patients move on a lower curve increasing their risk 
to become T2D (ie low DI given by a low insulin secretion and/or high insulin resistance). 
In this cohort, DI was significantly reduced in CHC but not in NAFLD (Figure 4). This was 
mainly because of the decreased insulin response during OGTT. On the contrary, NAFLD 
is on the same line as CT despite high insulin resistance (Figure 4). Thus, in this cohort of 
patients with NAFLD the insulin response is more than adequate to overcome the defect in 
peripheral insulin resistance thus maintaining glucose tolerance. This is probably because 
of the fact that most of these patients are non-obese. However, we cannot exclude that the 
high insulin response in the long term might result in ß-cell stress and dysfunction, thus 
predisposing to diabetes. 
We observed that subjects with increased liver fibrosis, in particular NAFLD patients, had 
lower DI due in part to decreased peripheral insulin sensitivity (OGIS index) but also to 
peripheral insulin concentrations. We cannot establish if these differences were because 
of pre-hepatic insulin secretion rates or hepatic insulin clearance since we did not measure 
C-peptide concentrations. In normal conditions, the liver clears up to 60% of the secreted 
insulin during the first pass, while it does not degrade C-peptide.44 In liver disease, and/or 
IR, insulin clearance is reduced in order to have higher insulin concentrations in the 
periphery.21, 45-47 Thus, we cannot establish if increased insulin concentration during OGTT 
is the result of increased insulin secretion or reduced hepatic clearance or both. However, 
a recent article has shown that despite NAFLD had a reduced insulin clearance this was 
dependent on reduced peripheral insulin sensitivity and subcutaneous fat, rather than the 
degree of liver steatosis.48 Moreover this is not a limit for the calculation of DI since, as we 
have shown recently, only peripheral insulin concentrations and not C-peptide are related 
to insulin sensitivity in a hyperbolic matter and thus insulin and not C-peptide should be 
used to calculate DI.20 
Another possible limitation is the inclusion in this analysis of mainly non-obese NAFLD 
patients in order to have a good match for BMI with the CHC cohort. Obesity is often 
associated to IR and alteration in β-cell function. However, even in morbid obese subjects, 
glucose tolerance is often preserved and presence of NAFLD is not associated to 
impairment in glucose stimulated insulin response.49 Moreover, parameters of β-cell 
function such as glucose sensitivity (ie dose-response insulin secretion-glucose 
concentration), first phase insulin secretion, and potentiation, do not appear to be 
substantially altered by obesity as long as glucose tolerance is maintained.50 
The degree of fibrosis was associated to a reduced OGIS only in NAFLD patients, and it 
was not associated with DI. On the contrary, DI was decreased with worsening of glucose 
intolerance in both NAFLD and CHC (r = −0.48, P < .0001). Why OGIS was associated to 
hepatic fibrosis only in patients with NAFLD is controversial. The most plausible 
explanation is that insulin resistance (IR) is the main driver of the hepatic pathological 
events that finally lead to liver fibrosis, and insulin per se exerts a direct fibrogenetic effect 
on hepatic stellate cells (HSCs).51, 52 As a confirmation, reduced OGIS was also observed 
in NAFLD patients with the higher NAS score (steatosis, lobular inflammation and 
ballooning) that can predispose to fibrosis. On the contrary, although diabetes has been 
reported to affect almost 15% of HCV patients,38 the pathogenesis of HCV-induced liver 
injury is mostly based on a series of virus-associated events.53 HCV proteins modulate 
hepatocyte apoptosis and necrosis leading to HSCs and fibrosis. In addition, HCV 
manipulates the immune system that initially attempts to eradicate the virus, but, in the 
setting of chronic infection, promotes hepatocyte damage and fibrosis through direct 
cellular toxicity and the release of inflammatory cytokines. Thus, we can speculate that the 
role of IR is of minor importance in determining the degree of liver fibrosis in CHC, and this 
is why liver fibrosis is associated with OGIS in NAFLD and not in CHC. 
In conclusion, the liver plays a central role in metabolic disturbances. The presence of both 
hepatic and pancreatic dysfunction are major defects that explain the increased risk of 
T2D in patients with liver disease. Although decreased OGIS was associated to the degree 
of steatosis, fibrosis and NAS score, patients with NAFLD are able to compensate the 
increased muscle IR modulating peripheral insulin concentrations. On the contrary, most of 
CHC patients have an impairment in insulin response to OGTT that increases their risk to 
develop T2D. While diagnosis of advanced fibrosis by non-invasive tests and treatment is 
well-defined in HCV patients, these aspects are challenging in NAFLD patients. OGIS 
measurement after OGTT should be performed in routine clinical practice to identify those 
NAFLD patients at risk of T2DM and with fibrosis. 
 
TABLE 1. Clinical characteristics of study subjects 
• Abbreviations: IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NFG, normal fasting glucose; 
NGT, normal glucose tolerance; NGT-IR, control normal glucose tolerant – insulin resistant; NGT-IS, 
controls normal glucose tolerant – insulin sensitive. 
• a Presence of steatosis at liver biopsy. 
• b P < 0.05 vs NGT-IS. 
• c P < 0.05 vs NGT-IR. 
• d P < 0.05 vs NAFLD. 
• e P < 0.05 vs CHC non-G3. 
TABLE 2. Clinical and metabolic characteristics of subjects with liver disease according 
to the degree of fibrosis 
• a P < .05 F2-F4 vs F0-F1. 
 
FIGURE 1 
Glucose (Panel A) and Insulin (Panel B) profile during a standard OGTT (75 g) in 
controls (insulin sensitive, NGT-IS and insulin resistant, NGT-IR), CHC and NAFLD. 
Statistical analysis P < .05: * vs NGT-IS, § vs NGT-IR, # vs CHC, ‡ vs NAFLD 
FIGURE 2 
Insulin sensitivity (OGIS index) and insulin secretion calculated as insulin response to 
OGTT in controls NGT-IS and NGT-IR, CHC and NAFLD (panel A and B); in CHC and 
NAFLD according to the degree of fibrosis (panel C and D); in NAFLD according to NAS 
score (panel E and F). The degree of fibrosis was increased with lower OGIS 
independent of BMI and with increased glucose intolerance in both NAFLD and CHC 
(r = −0.48, P < .0001). Statistical analysis P < .05: * vs NGT-IS, § vs NGT-IR, # vs NAFLD; ‡ vs 
low Fibrosis; ‡ vs NAS 1-3 
FIGURE 3 
Panel A. Disposition index (DI) trajectories in subjects with or without liver disease. A 
low DI is a sign of increased risk of type 2 diabetes. In this cohorts, insulin sensitive 
control subjects (NGT-IS), NAFL-NGT and NASH-NGT were on similar curves, indicating 
that NAFLD patients compensated the lower IS with increased insulin response during 
OGTT. Subjects with CHC-NGT have reduced DI, similar to NGT-IR, NAFL-IGT and 
NASH-IGT, while in CHC-IGT the DI was further reduced. Panel B shows the mean 
values of DI in each group (*P < .05 vs NGT-IS, §P < .05 vs NGT-IR, ‡P < .05 vs CHC-
NGT, #P < .05 vs NAFL-NGT $P < .05 vs NASH-NGT following Mann-Whitney comparison 
among groups) 
FIGURE 4 
The disposition index (DI) in controls (NGT-IS and NGT-IR), CHC and NAFLD (panel A); 
in CHC and NAFLD according to the degree of fibrosis (panel B); in NAFLD according to 
NAS score (panel C); in NAFL vs NASH score (panel D). The degree of fibrosis was not 
associated with DI. *P < .05 vs NGT-IS, §P < .05 vs NGT-IR, #P < .05 vs NAFLD; ‡P < .05 vs 
low NAS 1-3 
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